AGEP; hyper inflammatory response; rash; exhaustion; some back pain; Lost skin from entire body with exception of face; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 77-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 05Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 77 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Breast cancer - now cancer free" (unspecified if ongoing), notes: Other medical history: Breast cancer - now cancer free; "osteoporosis" (unspecified if ongoing); "somewhat high cholesterol" (unspecified if ongoing), notes: Other medical history: somewhat high cholesterol; "ARMD" (unspecified if ongoing), notes: Other medical history: ARMD (Age-related macular degeneration); "spinal arthritis" (unspecified if ongoing), notes: Other medical history: spinal arthritis; "irritable bowel" (unspecified if ongoing); "mild GERD" (unspecified if ongoing), notes: Other medical history: mild GERD; "generalized anxiety" (unspecified if ongoing), notes: Other medical history: generalized anxiety; "Known allergies: Latex" (unspecified if ongoing), notes: Known allergies: Latex. Concomitant medication(s) included: ESCITALOPRAM; BONIVA; ROSUVAST; ANASTROZ; DICYCLOMINE. Vaccination history included: BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Prev dose vaccine location=Right arm), administration date: 01Oct2021, when the patient was 76-year-old, for COVID-19 Immunization; Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer, Dose: 2), for COVID-19 Immunization; Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer, Dose: 1), for COVID-19 Immunization. The following information was reported: ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS (medically significant) with onset 06Apr2022, outcome "recovered with sequelae", described as "AGEP"; SKIN EXFOLIATION (medically significant) with onset 06Apr2022, outcome "recovered with sequelae", described as "Lost skin from entire body with exception of face"; FATIGUE (medically significant) with onset 06Apr2022, outcome "recovered with sequelae", described as "exhaustion"; INFLAMMATION (medically significant) with onset 06Apr2022, outcome "recovered with sequelae", described as "hyper inflammatory response"; RASH (medically significant) with onset 06Apr2022, outcome "recovered with sequelae"; BACK PAIN (medically significant) with onset 06Apr2022, outcome "recovered with sequelae", described as "some back pain". The events "AGEP" (Acute generalised exanthematous pustulosis), "hyper inflammatory response", "rash", "exhaustion", "some back pain" and "lost skin from entire body with exception of face" required physician office visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Dec2022) Negative, notes: Nasal Swab. Therapeutic measures were taken as a result of acute generalised exanthematous pustulosis, inflammation, rash, fatigue, back pain, skin exfoliation.  Clinical information: Patient stated, I developed what was diagnosed as AGEP within 24 hours. It did not resolve, but became a hyper inflammatory response resulting in rash, exhaustion, and some back pain. Lost skin from entire body with exception of face. Appears to have mostly resolved with steroid treatment after 3-4 months. Knocked me pretty much flat for the first 2 months. No Covid prior vaccination, covid tested post vaccination  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.